spacer
home > pmps > spring 2017 > is europe ready?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Is Europe Ready?

February saw an important milestone for all pharmaceutical manufacturers supplying the European market and their supply chain partners – the 9th marked the beginning of the two-year countdown until the EU’s Falsified Medicines Directive (EU-FMD) compliance mandate comes into force across Europe. From that date, pharma companies will no longer be able to legally put products on the European market unless they comply with the three critical ‘safety features’ requirements. Every pack of medicines must be:
  • Tamper-evidenced
  • Carrying a 2D data matrix encoding a unique identifier (UI)
  • The UI must have been uploaded into a Europe-wide system of repositories for systematic check-out at pharmacies
Achieving readiness to fulfil these conditions is a huge undertaking and the question being asked is: ‘How realistic is the prospect that Europe will be ready in February 2019?’ In order to answer this, let us consider the different areas of work in turn.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christoph Krähenbühl, Senior Director at 3C Excellis Europe, is widely recognised as a thought leader in pharma serialisation. He has been involved in serialisation schemes since 2006 as Serialisation Project Manager and Product Security Manager at AstraZeneca. Christoph has also been supporting the European stakeholder response to the EU-FMD as an expert on the European Federation of Pharmaceutical Industries and Associations team and as a member of the EMVO management team.
spacer
Christoph Krähenbühl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Reports


More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement